Ethos Discovery de novo study
Hemangiosarcoma (HSA) is an aggressive cancer in dogs and carries a poor prognosis. There are limited therapeutic options for the treatment of HSA, with none currently providing a significant opportunity for long-term survival. Ethos Discovery’s previous work in HSA has taught us that HSA is not a single cancer, but is rather at least four different subtypes of cancer, each characterized by a different genomic mutation. Previous studies evaluating drugs for the treatment of HSA have shown variable results and the discovery of these different subtypes could explain this phenomenon. Ethos Discovery now seeks to deliver a highly advanced clinical trial program investigating the use of novel drugs for the treatment of HSA with the goal of curing this aggressive cancer. This study will ask if drugs specifically matched to the genomic subtypes of patients with HSA will result in improved outcomes.
- Any dog that has had a splenectomy performed within the previous 30 days and was found to have HSA based on biopsy.
- No evidence of metastasis as determined via chest x-rays, abdominal ultrasound, or during surgery.
- Dogs weighing more than 5kg and less than 45kg
- The Oncology Service, Richmond, VA
- The Oncology Service, Springfield, VA
Enroll or request more information below